Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Summary
The purpose of this phase I/II trial study is to identify the best dose and evaluate how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
General Information
NCT#: NCT03368963
Study ID: IRB00098958
Trial Phase: Phase I/II
Trial Sponsor: Taiho Oncology, Inc., Ipsen Biopharmaceuticals, Emory University
Therapies Used in This Trial: irinotecan liposome injection, Trifluridine/Tipiricil